Fractyl Laboratories Inc., a Lexington, Mass.-based developer of minimally invasive procedural therapy that can reverse metabolic diseases, completed a $44m Series D financing. The round was led by an undisclosed new investor, joined by new investors GV, True Ventures, and the IDO Fund and returning investors General Catalyst, Bessemer Venture Partners, Domain Associates, Mithril Capital …